Patent classifications
A61M2025/0091
Treating upper airway nerve tissue
Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.
Low-profile extension for a catheter assembly
An extension for a catheter assembly may include a distal end and a proximal end. The distal end may include one or more cantilever arms and an insertion feature spaced apart from the cantilever arms. The insertion feature may be configured to insert into a lumen of a catheter adapter to provide a fluid connection between the catheter adapter and the extension. The one or more cantilever arms may be configured to engage in a snap-fit with the catheter adapter. The proximal end of the extension may include a female luer fitting.
SYSTEMS AND METHODS FOR MINIMALLY INVASIVE DRUG DELIVERY TO A SUBARACHNOID SPACE
Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.
Systems and methods for minimally invasive drug delivery to a subarachnoid space
Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.
METHODS OF DELIVERING THERAPEUTIC AGENTS TO THE OPTIC NERVE HEAD AND DEVICES FOR PRACTICING SAME
Provided are methods of delivering a therapeutic agent to the optic nerve head (ONH) of a subject. The methods comprise creating a sclerostomy posterior to the limbus of the subject and feeding a catheter with a distal needle tip tangentially into the sclerostomy. The methods further comprise tunneling the catheter through the suprachoroidal space (SCS) toward the ONH, and disposing the needle tip adjacent, or into, the ONH. The methods further comprise injecting the therapeutic agent adjacent or into the ONH. The methods find use in a variety of contexts, including but not limited to, treating an ONH-associated condition in a subject in need thereof. Examples of such conditions include, but are not limited to, optic neuropathies such as glaucoma, non-arteritic anterior ischemic optic neuropathy (NAION), and the like. Devices and kits that find use in practicing the methods of the present disclosure are also provided.
SYSTEMS AND METHODS FOR MINIMALLY INVASIVE DRUG DELIVERY TO A SUBARACHNOID SPACE
Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.
METHODS AND DEVICES FOR DELIVERING THERAPEUTIC MATERIALS TO THE INTERVERTEBRAL DISC
A method of delivering a therapeutic agent to a nucleus pulposus of an intervertebral disc is provided. The method comprises inserting a delivery tool containing the therapeutic agent through an anterior portion, a lateral portion, or an anterolateral portion of an annulus fibrosus and into the nucleus pulposus of the intervertebral disc; and delivering the therapeutic agent to the nucleus pulposus of the intervertebral disc. Devices and kits are also provided.
TREATING UPPER AIRWAY NERVE TISSUE
Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.
Treating upper airway nerve tissue
Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.
Endoscopic Fluid Aspiration Device
An endoscopic device for use in a patient's body in disclosed. The endoscopic device may include an outer sheath having a proximal end and a distal end, a suction tube inside the outer sheath, a handle coupled to the distal end of the outer sheath, and a cap on the proximal end of the outer sheath, positioned to seal the proximal end of the outer sheath, wherein the outer sheath comprises a sterile appliance, wherein the cap is structured to open in response to a force applied through the suction tube, and wherein the suction tube comprises an internal cavity.